News

Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference

SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation…

9 months ago

Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum

Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential…

9 months ago

AMBU FINANCIAL CALENDAR FOR 2023/24

This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as…

9 months ago

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and…

9 months ago

Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB

EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues…

9 months ago

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…

9 months ago

Spexis provides business update and announces financial results for the first half of 2023

Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of…

9 months ago

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics…

9 months ago

Vaccinex Announces Pricing of $9.6 Million Public Offering

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

9 months ago

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…

9 months ago